Advaxis, Inc. (NASDAQ:ADXS) – Jefferies Group issued their FY2022 earnings per share (EPS) estimates for Advaxis in a note issued to investors on Thursday, according to Zacks Investment Research. Jefferies Group analyst B. Amin forecasts that the biotechnology company will post earnings per share of $3.12 for the year.
ADXS has been the subject of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and set a $23.00 price objective on shares of Advaxis in a research report on Wednesday, November 8th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $19.00 price objective on shares of Advaxis in a research report on Monday, September 25th. Finally, ValuEngine cut shares of Advaxis from a “sell” rating to a “strong sell” rating in a research report on Tuesday, October 3rd.
Advaxis (NASDAQ ADXS) opened at $2.96 on Friday. The firm has a market cap of $122.26, a P/E ratio of -1.28 and a beta of 1.91. Advaxis has a 1 year low of $2.71 and a 1 year high of $10.06.
Advaxis (NASDAQ:ADXS) last posted its quarterly earnings results on Wednesday, December 20th. The biotechnology company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.02). Advaxis had a negative net margin of 776.63% and a negative return on equity of 114.00%. The firm had revenue of $1.76 million during the quarter, compared to analysts’ expectations of $3.05 million.
Several institutional investors and hedge funds have recently made changes to their positions in ADXS. Vanguard Group Inc. raised its holdings in shares of Advaxis by 9.2% in the 1st quarter. Vanguard Group Inc. now owns 1,663,010 shares of the biotechnology company’s stock valued at $13,587,000 after purchasing an additional 139,710 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Advaxis by 4.8% in the 1st quarter. Geode Capital Management LLC now owns 279,812 shares of the biotechnology company’s stock valued at $2,286,000 after purchasing an additional 12,736 shares in the last quarter. Schwab Charles Investment Management Inc. raised its holdings in shares of Advaxis by 6.1% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 128,504 shares of the biotechnology company’s stock valued at $1,050,000 after purchasing an additional 7,353 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Advaxis by 3.7% in the 2nd quarter. Rhumbline Advisers now owns 42,508 shares of the biotechnology company’s stock valued at $276,000 after purchasing an additional 1,530 shares in the last quarter. Finally, State of Wisconsin Investment Board acquired a new stake in shares of Advaxis in the 2nd quarter valued at $201,000. Institutional investors and hedge funds own 41.65% of the company’s stock.
In other Advaxis news, insider Robert Petit sold 12,625 shares of the stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $3.19, for a total transaction of $40,273.75. Following the sale, the insider now directly owns 237,265 shares in the company, valued at approximately $756,875.35. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Sara Bonstein sold 12,734 shares of the stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $3.19, for a total transaction of $40,621.46. Following the sale, the chief financial officer now owns 244,504 shares in the company, valued at $779,967.76. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 38,192 shares of company stock worth $122,615. 7.21% of the stock is owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “Jefferies Group Weighs in on Advaxis, Inc.’s FY2022 Earnings (ADXS)” was originally posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.thelincolnianonline.com/2018/01/14/advaxis-inc-adxs-expected-to-earn-fy2022-earnings-of-3-12-per-share-updated-updated.html.
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.